论文部分内容阅读
2012年3月2日,由《中国新药杂志》主办,雅培贸易上海有限公司协办的2012年中国生物仿制药政策专家研讨会在北京召开。参加本次研讨会的主要专家有中国医药工业科研开发促进会执行会长、《中国新药杂志》执行主编宋瑞霖、国家食品药品监督管理局药品注册司司长张伟、国家科技部科技战略研究院主任王宏广、中国食品药品检定研究院副院长王军志、《中国新药杂志》有限公司董事长石晟怡、中国生物技术股份有限公司总裁杨晓明、中国生物技术股份有限公司副总裁沈心亮、沈阳三生制药有限责任公司总裁娄竞、国家食品药品监督管
On March 2, 2012, a Symposium on Chinese Biosimilars Policy was held in Beijing in collaboration with Abbott Trading Shanghai Co., Ltd., sponsored by China New Drug Magazine. The key experts participating in this seminar are executive chairman of China Pharmaceutical Industry Research and Development Promotion Association, Song Ruilin, executive editor of “China New Drugs Magazine”, Zhang Wei, director of Drug Registration Department of State Food and Drug Administration, Ministry of Science and Technology Strategy Research Institute Director Wang Hongguang, vice president of China Food and Drug Administration Wang Junzhi, chairman of China New Drugs Magazine Co., Ltd. Shi Shengyi, president of China Biotechnology Co., Ltd. Yang Xiaoming, vice president of China Biotechnology Co., Ltd. Shen Xinliang, Shenyang Sansheng Pharmaceutical Co., Ltd. Lou Jing, president of the company, the State Food and Drug Administration